The Institute for Applied Biomedicine - Researcher Biographies

Research Committee
Institute for Applied Biomedicine

Institute for Applied Biomedicine's Research Committee is responsible for the research and development of a cure for AIDS and other immune system disorders. As the organization's scientific advisory board, its members are tasked with reviewing study plans, analyzing data, and providing technical advice to the Board of Directors.

Frank C. Andrews, Ph.D. is a Professor of Chemistry and Biochemistry at the University of California, Santa Cruz. Dr. Andrews is the author of many scientific publications, three Chemistry textbooks as well as a book entitled The Art and Practice of Loving. Dr. Andrews is the recipient of eight teaching awards, both local and national, and is the founding Board President of the Institute of Applied Biomedicine. Dr. Andrews received a Bachelor of Science Degree in Chemistry from Kansas State University, a Master of Arts Degree in Chemistry from Harvard University and was awarded his Doctorate in Chemical Physics from Harvard, as well.

H. Michael Ellerby, Ph.D. is an Assistant Professor at the Buck Institute for Age Research and a Professor at Tuoro University College of Osteopathic Medicine.

Evan Hermel, Ph. D. is an Associate Professor of Microbiology and Immunology at Touro University College of Osteopathic Medicine in Vallejo, Calif. Since 2000, Dr. Hermel has also been a Visiting Scholar at the Buck Institute for Age Research in Novato, Calif. Dr. HermelÕs research interests are in immunogenetics, neurogenetics and cellular immunology. Dr. Hermel received a Bachelor of Arts Degree from Hofstra University, and was awarded his Ph.D. from the University of Texas Southwestern Medical Center, where he was a student of Kirsten Fischer-Lindahl, Ph.D. Dr. Hermel did his Postdoctoral Fellowship in the lab of John Monaco, Ph.D. at the University of Cincinnati.

Edward G. Spack, Ph.D. is currently building a vaccine group at SRI International in Menlo Park, Calif, which consults on projects ranging from novel AIDS vaccine strategies to biodefense projects attempting to neutralize botulism, plague and the West Nile virus. As well, Dr. Spack is the Senior Director of the PharmaSTART program; a consortium of SRI and four California universities (Stanford, UC Berkeley, UC San Diego and UC San Francisco) designed to chaperone discoveries from the laboratory bench to the clinic. Dr. Spack has worked in three San Francisco Bay Area biotech companies (Anergen, Valentis and InterMune) for a total of 14 years, with the bulk of his experience in the biologic drugs including humanized monoclonal antibodies, recombinant proteins and peptide vaccines. Dr. Spack has also served on the Board of Directors and the scientific advisory board of the National Myasthenia Gravis Foundation. Dr. Spack was awarded his Doctorate in Cellular Immunology at the Johns Hopkins University and held a post-doctoral fellowship at Stanford University.

John Winterle, Ph. D. is a Research Associate at the University of California, Santa Cruz. Dr. Winterle has served on the Board of Directors since 1999 and as the Director of Research since 2001. Dr. WinterleÕs background includes positions as the Director and Department Head at Syntex Research (Institute of Pharmaceutical Sciences), as well as Roche Bioscience in Palo Alto, CA. Dr. Winterle has participated in the development and commercial licensing of five pharmaceutical products including ganciclovir and naproxen, and has 28 scientific publications and 16 significant registration documents on file. Dr. Winterle received a Bachelor of Science Degree (Honors) in Chemistry from Florida State University, and was awarded his Doctorate in Chemistry from the California Institute of Technology. He is also a patent agent.